Annual Cash & Cash Equivalents
$3.48 M
-$7.94 M-69.51%
December 31, 2023
Summary
- As of February 7, 2025, OGEN annual cash & cash equivalents is $3.48 million, with the most recent change of -$7.94 million (-69.51%) on December 31, 2023.
- During the last 3 years, OGEN annual cash & cash equivalents has fallen by -$14.16 million (-80.25%).
- OGEN annual cash & cash equivalents is now -87.22% below its all-time high of $27.27 million, reached on December 31, 2021.
Performance
OGEN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.14 M
+$1.80 M+133.13%
September 30, 2024
Summary
- As of February 7, 2025, OGEN quarterly cash and cash equivalents is $3.14 million, with the most recent change of +$1.80 million (+133.13%) on September 30, 2024.
- Over the past year, OGEN quarterly cash and cash equivalents has dropped by -$339.50 thousand (-9.75%).
- OGEN quarterly cash and cash equivalents is now -91.39% below its all-time high of $36.50 million, reached on March 31, 2021.
Performance
OGEN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
OGEN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -69.5% | -9.8% |
| 3 y3 years | -80.3% | -9.8% |
| 5 y5 years | -82.8% | -9.8% |
OGEN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -87.2% | at low | -88.5% | +133.1% |
| 5 y | 5-year | -87.2% | at low | -91.4% | +133.1% |
| alltime | all time | -87.2% | +2537.0% | -91.4% | -100.0% |
Oragenics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.14 M(+133.1%) |
| Jun 2024 | - | $1.35 M(-34.9%) |
| Mar 2024 | - | $2.07 M(-40.5%) |
| Dec 2023 | $3.48 M(-69.5%) | $3.48 M(-39.6%) |
| Sep 2023 | - | $5.77 M(-10.9%) |
| Jun 2023 | - | $6.47 M(-29.3%) |
| Mar 2023 | - | $9.16 M(-19.9%) |
| Dec 2022 | $11.43 M(-58.1%) | $11.43 M(-18.1%) |
| Sep 2022 | - | $13.95 M(-21.9%) |
| Jun 2022 | - | $17.87 M(-16.4%) |
| Mar 2022 | - | $21.37 M(-21.6%) |
| Dec 2021 | $27.27 M(+54.6%) | $27.27 M(-9.0%) |
| Sep 2021 | - | $29.95 M(-13.4%) |
| Jun 2021 | - | $34.57 M(-5.3%) |
| Mar 2021 | - | $36.50 M(+106.9%) |
| Dec 2020 | $17.64 M(-3.4%) | $17.64 M(+75.6%) |
| Sep 2020 | - | $10.04 M(+4.3%) |
| Jun 2020 | - | $9.63 M(-33.0%) |
| Mar 2020 | - | $14.37 M(-21.3%) |
| Dec 2019 | $18.27 M(-9.6%) | $18.27 M(-18.1%) |
| Sep 2019 | - | $22.29 M(-13.3%) |
| Jun 2019 | - | $25.72 M(-12.4%) |
| Mar 2019 | - | $29.35 M(+45.2%) |
| Dec 2018 | $20.21 M(+227.7%) | $20.21 M(+46.3%) |
| Sep 2018 | - | $13.81 M(+250.5%) |
| Jun 2018 | - | $3.94 M(-17.2%) |
| Mar 2018 | - | $4.76 M(-22.8%) |
| Dec 2017 | $6.17 M(+51.1%) | $6.17 M(+110.9%) |
| Sep 2017 | - | $2.92 M(+40.0%) |
| Jun 2017 | - | $2.09 M(-4.0%) |
| Mar 2017 | - | $2.18 M(-46.7%) |
| Dec 2016 | $4.08 M(-19.7%) | $4.08 M(-20.2%) |
| Sep 2016 | - | $5.12 M(-6.2%) |
| Jun 2016 | - | $5.46 M(+62.1%) |
| Mar 2016 | - | $3.37 M(-33.8%) |
| Dec 2015 | $5.08 M(-51.3%) | $5.08 M(-24.6%) |
| Sep 2015 | - | $6.74 M(-16.2%) |
| Jun 2015 | - | $8.04 M(-11.2%) |
| Mar 2015 | - | $9.05 M(-13.4%) |
| Dec 2014 | $10.45 M(-35.8%) | $10.45 M(-11.2%) |
| Sep 2014 | - | $11.76 M(-8.8%) |
| Jun 2014 | - | $12.90 M(-11.9%) |
| Mar 2014 | - | $14.64 M(-10.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $16.28 M(+64.0%) | $16.28 M(+96.9%) |
| Sep 2013 | - | $8.27 M(+29.8%) |
| Jun 2013 | - | $6.37 M(-23.7%) |
| Mar 2013 | - | $8.35 M(-15.9%) |
| Dec 2012 | $9.93 M(+5681.0%) | $9.93 M(-15.6%) |
| Sep 2012 | - | $11.76 M(+940.1%) |
| Jun 2012 | - | $1.13 M(+16.8%) |
| Mar 2012 | - | $967.90 K(+463.7%) |
| Dec 2011 | $171.70 K(+30.0%) | $171.70 K(>+9900.0%) |
| Sep 2011 | - | $0.00(0.0%) |
| Jun 2011 | - | $0.00(-100.0%) |
| Mar 2011 | - | $56.40 K(-57.3%) |
| Dec 2010 | $132.10 K(-56.2%) | $132.10 K(-73.9%) |
| Sep 2010 | - | $505.20 K(+133.0%) |
| Jun 2010 | - | $216.80 K(-52.8%) |
| Mar 2010 | - | $459.10 K(+52.2%) |
| Dec 2009 | $301.60 K(-74.1%) | $301.60 K(-58.4%) |
| Sep 2009 | - | $725.00 K(-60.2%) |
| Jun 2009 | - | $1.82 M(+3042.8%) |
| Mar 2009 | - | $57.90 K(-95.0%) |
| Dec 2008 | $1.17 M(+145.2%) | $1.17 M(-56.8%) |
| Sep 2008 | - | $2.70 M(-25.7%) |
| Jun 2008 | - | $3.63 M(+84.8%) |
| Mar 2008 | - | $1.97 M(+313.6%) |
| Dec 2007 | $475.50 K(-32.8%) | $475.50 K(-49.2%) |
| Sep 2007 | - | $935.70 K(+517.6%) |
| Jun 2007 | - | $151.50 K(-79.8%) |
| Mar 2007 | - | $749.70 K(+6.0%) |
| Dec 2006 | $707.30 K(-24.6%) | $707.30 K(+50.5%) |
| Sep 2006 | - | $470.00 K(-45.5%) |
| Jun 2006 | - | $861.70 K(+18.8%) |
| Mar 2006 | - | $725.50 K(-22.6%) |
| Dec 2005 | $937.80 K(-74.4%) | $937.80 K(+10.1%) |
| Sep 2005 | - | $851.50 K(-49.4%) |
| Jun 2005 | - | $1.68 M(-29.4%) |
| Mar 2005 | - | $2.38 M(-35.0%) |
| Dec 2004 | $3.67 M(+2.3%) | $3.67 M(-15.0%) |
| Sep 2004 | - | $4.31 M(-16.2%) |
| Jun 2004 | - | $5.15 M(-14.4%) |
| Mar 2004 | - | $6.01 M(+67.8%) |
| Dec 2003 | $3.58 M | $3.58 M(+111.7%) |
| Sep 2003 | - | $1.69 M(-9.4%) |
| Jun 2003 | - | $1.87 M |
FAQ
- What is Oragenics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Oragenics?
- What is Oragenics annual cash & cash equivalents year-on-year change?
- What is Oragenics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Oragenics?
- What is Oragenics quarterly cash and cash equivalents year-on-year change?
What is Oragenics annual cash & cash equivalents?
The current annual cash & cash equivalents of OGEN is $3.48 M
What is the all time high annual cash & cash equivalents for Oragenics?
Oragenics all-time high annual cash & cash equivalents is $27.27 M
What is Oragenics annual cash & cash equivalents year-on-year change?
Over the past year, OGEN annual cash & cash equivalents has changed by -$7.94 M (-69.51%)
What is Oragenics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of OGEN is $3.14 M
What is the all time high quarterly cash and cash equivalents for Oragenics?
Oragenics all-time high quarterly cash and cash equivalents is $36.50 M
What is Oragenics quarterly cash and cash equivalents year-on-year change?
Over the past year, OGEN quarterly cash and cash equivalents has changed by -$339.50 K (-9.75%)